GUARDANT HEALTH, INC. (GH) Spending and interest coverage
- R&D / revenue · 12 months: Value 31.76%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 16.17%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 31.76% | Research and development expense / revenue. Period ending 2026-06-30. $375.79M ÷ $1.18B × 100 ≈ 31.76% |
| Stock-based compensation / revenue · 12 months | 16.17% | Share-based compensation / revenue. Period ending 2026-06-30. $191.33M ÷ $1.18B × 100 ≈ 16.17% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 375.79M USD | Research and Development Expense |
| Revenue | 1.18B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 191.33M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -470.26M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $375.79M | $1.18B | $191.33M | $-470.26M | (m) | 31.76% | 16.17% | (m) | (m) |
| 2026-03-31 | $366.71M | $1.08B | $176.07M | $-447.56M | (m) | 33.95% | 16.30% | (m) | (m) |
| 2025-12-31 | $364.19M | $982.02M | $166.22M | $-437.25M | (m) | 37.09% | 16.93% | (m) | (m) |
| 2025-09-30 | $359.47M | $902.57M | $159.39M | $-442.41M | (m) | 39.83% | 17.66% | (m) | (m) |
| 2025-06-30 | $356.82M | $828.85M | $166.35M | $-460.75M | (m) | 43.05% | 20.07% | (m) | (m) |
| 2025-03-31 | $352.47M | $774.00M | $151.13M | $-454.95M | (m) | 45.54% | 19.53% | (m) | (m) |
| 2024-12-31 | $347.75M | $739.02M | $140.41M | $-443.59M | (m) | 47.06% | 19.00% | (m) | (m) |
| 2024-09-30 | $344.07M | $692.26M | $128.37M | $-515.14M | (m) | 49.70% | 18.54% | (m) | (m) |
| 2024-06-30 | $350.61M | $643.81M | $100.42M | $-511.36M | (m) | 54.46% | 15.60% | (m) | (m) |
| 2024-03-31 | $357.87M | $603.73M | $95.53M | $-530.35M | $2.58M | 59.28% | 15.82% | -205.64× | Reported |
| 2023-12-31 | $367.19M | $563.95M | $90.76M | $-564.73M | $2.58M | 65.11% | 16.09% | -219.06× | Reported |
| 2023-09-30 | $383.92M | $535.78M | $90.14M | $-513.33M | $2.58M | 71.65% | 16.82% | -199.20× | Reported |
| 2023-06-30 | $390.08M | $510.16M | $88.96M | $-544.39M | $2.58M | 76.46% | 17.44% | -211.25× | Reported |
| 2023-03-31 | $385.18M | $482.15M | $92.15M | $-555.10M | $2.58M | 79.89% | 19.11% | -215.40× | Reported |
| 2022-12-31 | $373.81M | $449.54M | $94.69M | $-544.38M | $2.58M | 83.15% | 21.06% | -211.24× | Reported |
| 2022-09-30 | $340.25M | $430.75M | $97.84M | $-496.47M | $2.58M | 78.99% | 22.71% | -192.73× | Reported |
| 2022-06-30 | $311.20M | $408.13M | $112.22M | $-459.15M | $2.58M | 76.25% | 27.50% | -178.24× | Reported |
| 2022-03-31 | $289.47M | $391.09M | $121.18M | $-426.48M | $2.58M | 74.02% | 30.99% | -165.62× | Reported |
| 2021-12-31 | $263.22M | $373.65M | $151.45M | $-411.00M | $2.58M | 70.45% | 40.53% | -159.49× | Reported |
| 2021-09-30 | $230.48M | $343.86M | $181.35M | $-403.96M | $6.67M | 67.03% | 52.74% | -60.56× | Reported |
| 2021-06-30 | $195.76M | $323.65M | $201.54M | $-370.92M | $6.03M | 60.48% | 62.27% | -61.47× | Reported |
| 2021-03-31 | $168.35M | $297.88M | $192.84M | $-327.90M | $5.40M | 56.52% | 64.74% | -60.72× | Reported |
| 2020-12-31 | $149.86M | $286.73M | $144.11M | $-254.95M | $4.77M | 52.27% | 50.26% | -53.49× | Reported |
| 2020-09-30 | $135.46M | $271.31M | $92.42M | $-189.75M | $351.00K | 49.93% | 34.07% | -540.59× | Reported |
| 2020-06-30 | $123.78M | $257.59M | $42.71M | $-132.97M | $623.00K | 48.05% | 16.58% | -213.44× | Reported |
| 2020-03-31 | $106.99M | $245.23M | $20.11M | $-93.62M | $900.00K | 43.63% | 8.20% | -104.02× | Reported |
| 2019-12-31 | $86.29M | $214.38M | $16.95M | $-82.37M | $1.18M | 40.25% | 7.91% | -69.75× | Reported |
| 2019-09-30 | $77.07M | $184.35M | $14.45M | $-83.80M | $1.16M | 41.81% | 7.84% | -72.30× | Reported |
| 2019-06-30 | $66.75M | $145.19M | $10.79M | $-90.52M | $1.18M | 45.97% | 7.43% | -76.52× | Reported |
| 2019-03-31 | $58.77M | $110.60M | $8.76M | $-97.96M | $1.21M | 53.14% | 7.92% | -80.76× | Reported |
| 2018-12-31 | $50.71M | $90.64M | $6.85M | $-92.94M | $1.25M | 55.95% | 7.56% | -74.29× | Reported |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $25.56M | $49.84M | $3.67M | $-76.61M | $2.70M | 51.29% | 7.36% | -28.35× | Reported |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $10.86M | $25.25M | $1.97M | $-43.85M | $3.02M | 43.01% | 7.81% | -14.53× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| QUEST DIAGNOSTICS INC (DGX) | United States | $26.096B | 22.09 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |